Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Caspofungin
Drug ID BADD_D00376
Description Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
Indications and Usage For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
Marketing Status Prescription
ATC Code J02AX04
DrugBank ID DB00520
KEGG ID D07626
MeSH ID D000077336
PubChem ID 2826718
TTD Drug ID D00ZCN
NDC Product Code Not Available
Synonyms Caspofungin | Cancidas | MK 0991 | MK-0991 | MK0991 | Caspofungin MSD | L 743,872 | L-743,872 | L743,872 | L-743872 | L743872 | L 743872 | Caspofungin Acetate
Chemical Information
Molecular Formula C52H88N10O15
CAS Registry Number 162808-62-0
SMILES CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O) C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cough22.02.03.001--
Death08.04.01.0010.001931%
Death neonatal08.04.01.002; 18.04.01.0020.000184%
Decubitus ulcer23.03.11.006--Not Available
Dermatitis23.03.04.002--Not Available
Dermatitis atopic23.03.04.016; 10.01.04.004--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.002--
Dyspnoea paroxysmal nocturnal22.02.01.018; 02.01.03.004--Not Available
Electrolyte imbalance14.05.01.002--Not Available
Eosinophil count increased13.01.06.004--Not Available
Eosinophilia01.02.04.0010.001410%
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Eye disorder06.08.03.001--Not Available
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.004--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fatigue08.01.01.002--
Febrile neutropenia01.02.03.002; 08.05.02.0040.000705%
Feeling abnormal08.01.09.014--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 10 Pages